Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2022 | 1222 | 1.390 |
Why?
|
| Biomarkers, Tumor | 8 | 2022 | 524 | 1.270 |
Why?
|
| Glypicans | 3 | 2009 | 6 | 0.870 |
Why?
|
| Immunohistochemistry | 6 | 2016 | 896 | 0.700 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2022 | 176 | 0.640 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 309 | 0.600 |
Why?
|
| Keratins | 1 | 2016 | 31 | 0.500 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2014 | 44 | 0.490 |
Why?
|
| Curettage | 2 | 2020 | 7 | 0.470 |
Why?
|
| Antibodies | 1 | 2016 | 187 | 0.470 |
Why?
|
| Uterine Diseases | 1 | 2014 | 9 | 0.430 |
Why?
|
| Endometrium | 1 | 2014 | 31 | 0.420 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2014 | 2 | 0.410 |
Why?
|
| Specimen Handling | 1 | 2014 | 61 | 0.410 |
Why?
|
| Biopsy | 1 | 2014 | 456 | 0.380 |
Why?
|
| Mastectomy, Segmental | 2 | 2022 | 48 | 0.350 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 74 | 0.250 |
Why?
|
| Female | 18 | 2022 | 34030 | 0.240 |
Why?
|
| Melanoma | 1 | 2009 | 333 | 0.230 |
Why?
|
| Mullerian Ducts | 1 | 2004 | 5 | 0.220 |
Why?
|
| Urinary Bladder Diseases | 1 | 2004 | 10 | 0.220 |
Why?
|
| Urinary Bladder | 1 | 2004 | 47 | 0.210 |
Why?
|
| Humans | 22 | 2022 | 65141 | 0.190 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2022 | 67 | 0.180 |
Why?
|
| Mammography | 2 | 2022 | 290 | 0.180 |
Why?
|
| Microscopy | 1 | 2022 | 99 | 0.170 |
Why?
|
| Colposcopy | 1 | 2020 | 20 | 0.160 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 5614 | 0.160 |
Why?
|
| Cervix Uteri | 1 | 2020 | 58 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2022 | 145 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 366 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 151 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2018 | 10 | 0.140 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 26 | 0.140 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2018 | 61 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2022 | 710 | 0.110 |
Why?
|
| Cytodiagnosis | 2 | 2022 | 46 | 0.110 |
Why?
|
| Middle Aged | 7 | 2020 | 18273 | 0.110 |
Why?
|
| Aged | 6 | 2018 | 14963 | 0.100 |
Why?
|
| Neoplasms, Fibroepithelial | 1 | 2014 | 3 | 0.100 |
Why?
|
| Observer Variation | 1 | 2014 | 216 | 0.100 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2014 | 39 | 0.100 |
Why?
|
| Coloring Agents | 1 | 2012 | 50 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2012 | 52 | 0.090 |
Why?
|
| Neuroendocrine Tumors | 1 | 2012 | 20 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 32 | 0.090 |
Why?
|
| Prognosis | 2 | 2014 | 1785 | 0.090 |
Why?
|
| Tonsillar Neoplasms | 1 | 2011 | 1 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 1163 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2011 | 53 | 0.090 |
Why?
|
| Mesothelioma, Cystic | 1 | 2011 | 1 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 130 | 0.090 |
Why?
|
| Papillomaviridae | 1 | 2011 | 59 | 0.080 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 213 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 33 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 30 | 0.080 |
Why?
|
| Adult | 5 | 2020 | 17358 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1585 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 794 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 513 | 0.080 |
Why?
|
| Tomography, Optical Coherence | 1 | 2012 | 235 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 261 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 35 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 354 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2012 | 1016 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 108 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 166 | 0.070 |
Why?
|
| Male | 4 | 2011 | 31055 | 0.050 |
Why?
|
| Radar | 1 | 2022 | 4 | 0.050 |
Why?
|
| Wireless Technology | 1 | 2022 | 14 | 0.050 |
Why?
|
| Egypt | 1 | 2022 | 6 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 704 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2022 | 27 | 0.040 |
Why?
|
| Breast | 1 | 2022 | 191 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2022 | 134 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 182 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 30 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 287 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2018 | 190 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2018 | 232 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 325 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 544 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2012 | 34 | 0.020 |
Why?
|
| Optics and Photonics | 1 | 2012 | 13 | 0.020 |
Why?
|
| Fluorescence Polarization | 1 | 2012 | 32 | 0.020 |
Why?
|
| Methylene Blue | 1 | 2012 | 23 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 240 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 401 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 309 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 231 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2012 | 422 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 432 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2012 | 299 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 673 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 220 | 0.020 |
Why?
|
| Asthma | 1 | 2011 | 483 | 0.010 |
Why?
|
| Hypertension | 1 | 2011 | 612 | 0.010 |
Why?
|
| Neoplasms | 1 | 2012 | 1367 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6865 | 0.010 |
Why?
|